Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

20041,715 citationsJournal Articlebronze Open Access

Authors

Roy S. Herbst · Memorial Sloan Kettering Cancer Center

Giuseppe Giaccone · Memorial Sloan Kettering Cancer Center

Joan H. Schiller · Memorial Sloan Kettering Cancer Center

Ronald B. Natale · Memorial Sloan Kettering Cancer Center

Vincent A. Miller · Memorial Sloan Kettering Cancer Center

Christian Manegold · Memorial Sloan Kettering Cancer Center

Giorgio V. Scagliotti

Abstract

Gefitinib showed no added benefit in survival, TTP, or RR compared with standard chemotherapy alone. This large, placebo-controlled trial confirmed the favorable gefitinib safety profile observed in phase I and II monotherapy trials.

Topics & Keywords

Lung Cancer Treatments and Mutations Colorectal Cancer Treatments and Studies HER2/EGFR in Cancer Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 22, Issue 5, pp. 785-794

DOI: 10.1200/jco.2004.07.215

Field-Weighted Citation Impact: 152.15